Log In Sign up
The largest database of trusted experimental protocols

Gsk2879552

Manufactured by Chemietek
Visit Supplier
Sourced in United States

GSK2879552 is a small molecule compound that inhibits the activity of an unspecified protein target. It is suitable for use in research applications.

Automatically generated - may contain errors

Lab products found in correlation

Gsk126, by Chemietek (1 mentions) Unc0638, by Merck Group (1 mentions) S2101, by Merck Group (1 mentions) Epz 5676, by Chemietek (1 mentions) Sgc0946, by Merck Group (1 mentions) Gsk j1, by Merck Group (1 mentions) Gsk lsd1, by Merck Group (1 mentions) Sp2509, by Selleck Chemicals (1 mentions)

2 protocols using gsk2879552

1

Epigenetic Modulators: Inhibitor Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The H3K4 methyltransferase LSD1 inhibitor S2101 was purchased from Merck Millipore (Burlington, MA, USA). The LSD1 inhibitor GSK2879552, H3K27 methyltransferase EZH2 inhibitor GSK126, and H3K79 methyltransferase DOT1L inhibitor EPZ-5676 were all purchased from Chemietek (Indianapolis, IN, USA). The H3K9 methyltransferase G9a inhibitor UNC0638, H3K27 demethylase JMJD3/UTX inhibitor GSKJ1, DOT1L inhibitor SGC0946, and MYC inhibitor 10058-F4 were all purchased from Sigma-Aldrich (St. Louis, MO, USA).
Ishiguro K., Kitajima H., Niinuma T., Ishida T., Maruyama R., Ikeda H., Hayashi T., Sasaki H., Wakasugi H., Nishiyama K., Shindo T., Yamamoto E., Kai M., Sasaki Y., Tokino T., Nakase H, & Suzuki H. (2019). DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling. Haematologica, 104(1), 155-165.
+ Open protocol
+ Expand
2

LSD1 Inhibition Dynamics in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Early inhibition of LSD1 (LSD1iearly) was performed by addition of the irreversible LSD1 inhibitor tranylcypromine (TCP) to cell culture wells on days 7, 8 and 9 at a final concentration of 0.5 µM. Late inhibition of LSD1 (LSD1ilate) was performed by addition of TCP to cell culture wells on days 10, 11 and 12 at a final concentration of 0.5 µM. Additional LSD1 inhibitors used to perform LSD1iearly and LSD1ilate experiments were SP2509 (Selleck Chemicals), GSK-LSD1 (Sigma) and GSK2879552 (Chemietek); and experiments were performed in the same way as with TCP, at a final concentrations of 1 μM.
Vinckier N.K., Patel N.A., Geusz R.J., Wang A., Wang J., Matta I., Harrington A.R., Wortham M., Wetton N., Wang J., Jhala U.S., Rosenfeld M.G., Benner C.W., Shih H.P, & Sander M. (2020). LSD1-mediated enhancer silencing attenuates retinoic acid signalling during pancreatic endocrine cell development. Nature Communications, 11, 2082.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!